Communicating Research

With billions of dollars in comparative effectiveness research (CER) set for completion in the near future, there will be broader discussions about the findings and what those findings might mean for patients and other health care decision makers. As part of this discussion, questions such as who can discuss and share these CER findings publicly, and how will the findings be communicated, also must be addressed.

Communicating Information

The pharmaceutical industry is highly regulated when it comes to discussing health care information, while other groups have wide latitude—or even complete freedom—in what they can say. While there are valid reasons for the regulation of some communication (marketing messages and materials, for example), there also are instances where it would be in the greater interest of public health for the sponsor of a particular drug to be allowed to respond to research or easily correct misinformation beyond solicited medical information. When it comes to CER, would the industry be able to discuss or share those studies, or even call for corrections on ones with serious flaws?

Communicating to Clinicians

CER will be further amplified through academic detailing initiatives, in which government or academic institutions train health experts to discuss CER with clinicians. In the United States, the Agency for Healthcare Research and Quality is leading the multi-million dollar federal initiative that will start off by targeting 1,300 primary care clinicians and 200 health systems. The federal government is not alone in its efforts-–states including Vermont, Pennsylvania, South Carolina and Maine have been conducting academic detailing for a number of years.

Additionally, CER information will be further disseminated via continuing medical education programs and payer review guides.

These programs can be useful in providing physicians and payers with information that they might not have been aware of otherwise. However, it is not clear as to where the checks and balances may exist in the oversight of government-sponsored detailing, in the same way it is required of industry.

Challenges for Patients

There are thousands of pages of health information available on the Internet, in medical journals, and other sources. Sifting through the information is daunting for a health care professional, let alone a patient. With more information becoming available, it will be even more important to ensure that patients have access to a broad amount of correct, verified information and know where to find it.

Unfortunately, sometimes incorrect information is shared broadly, and it can be difficult to quickly correct the misinformation and make sure that consumers are properly educated. Acting on poor or faulty information could lead to serious health consequences for patients.

NPC explored these communications challenges during a conference, Asymmetry in the Ability to Communicate CER Findings, through its sponsorship of a Health Affairs issue and video interviews with experts, among other activitites.

Newsletter Volume

E.V.I.dently June 2016

MessageNPC Looks at Updated ASCO Framework, Conversation Around ValueThe American Society of Clinical Oncology (ASCO) released its updated value...
Blog Post

CER Tweets of the Week: PIPC Briefing on Value Frameworks, Evidence-Based Medicine in Health Journalism (June 20-24, 2016)

Last week, comparative effectiveness research (CER) stakeholders tweeted about the Partnership to Improve Patient Care’s (@PIPCpatients)...
Blog Post

Improving the Exchange of Health Care Economic Data

One area of interest to the National Pharmaceutical Council (NPC) and our member biopharmaceutical companies—and an area we’ve focused on for several...
Blog Post

FDA/CMS Summit Offers Opportunity to Focus on Value

From the 21st Century Cures Act to negotiations about reauthorizing the Prescription Drug User Fee Act (PDUFA), much of this year has been focused on...
Press Release

NPC Comments on Appointment of AHRQ Director

Washington, DC, August 19, 2013—National Pharmaceutical Council (NPC) President Dan Leonard today released the following statement about the...
Press Release

Research Outlines Key Factors Influencing the Adoption of New Evidence Into Medical Practice

Washington, DC (July 10, 2013)—Research published today in the Journal of Comparative Effectiveness Research outlines influential factors that impact...
Press Release

NPC Conference to Address Questions on Ability to Share Health Research Findings Health

(Washington, DC, February 6, 2012)--To examine key issues around asymmetries, or inequalities, in communicating health information coming from the...
Press Release

National Pharmaceutical Council Examines Optimal Process for Prioritizing Comparative Effectiveness Research

WASHINGTON, DC (December 5, 2011)--With millions of dollars in funding set aside for comparative effectiveness research (CER) and countless...
Commentary and Testimony Page

Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?

A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...
Commentary and Testimony Page

Current Challenges in Comparative Effectiveness Research

[[{"fid":"376","view_mode":"teaser","type":"media","attributes":{"height":"390","width":"640","border":"0","alt":"Current Challenges in Comparative...
Commentary and Testimony Page

Ensuring a Free Flow of CER Information

When a person with a health issue jumps online to research his or her condition, it can be challenging to separate fact from fiction in the sea of...
Commentary and Testimony Page

Asymmetry in the Ability to Communicate CER Findings: Ethics and Issues for Informed Decision Making

The number of voices in the comparative effectiveness research (CER) conversation is continuing to grow, but not all stakeholders have the same...
YouTube Videos

Communicating CER Findings: Changes to FDAMA 114?

With his commentary in the New England Journal of Medicine, Tufts Medical Center Economist Dr. Peter Neumann re-sparked the debate about the type of...
YouTube Videos

PCORI Outlines Efforts to Engage Patients

Dr. Rachael Fleurence, Scientist,Patient-Centered Outcomes Research Institute, outlines the many ways heragency is engaging patients and other...
Blog Post

CER Tweets of the Week: PIPC Briefing on Value Frameworks, Evidence-Based Medicine in Health Journalism (June 20-24, 2016)

Last week, comparative effectiveness research (CER) stakeholders tweeted about the Partnership to Improve Patient Care’s (@PIPCpatients)...
Blog Post

Improving the Exchange of Health Care Economic Data

One area of interest to the National Pharmaceutical Council (NPC) and our member biopharmaceutical companies—and an area we’ve focused on for several...
Blog Post

FDA/CMS Summit Offers Opportunity to Focus on Value

From the 21st Century Cures Act to negotiations about reauthorizing the Prescription Drug User Fee Act (PDUFA), much of this year has been focused on...
Blog Post

#TBT: Amarin, Biopharmaceutical Communications and a Look Back at Caronia

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...

When Does FDAMA Section 114 Apply? Ten Case Studies

Understanding how treatments work in the real world is an important task for health plans,...

Communicating About Comparative Effectiveness Research: A Health Affairs Symposium on the Issues

One of many issues connected with comparative effectiveness research is how the findings will be...

Comparative Effectiveness Research Toolkit

NPC's CER Toolkit includes key articles and research to help you understand comparative...